Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

NCT02049866 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Adult Idiopathic Generalized Osteoporosis

Interventions

DRUG: Denosumab

Sponsor

Elizabeth Shane

Collaborators

[object Object]